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Abstract
AIM
To determine whether successful treatment with direc-
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Retrospective Study
tacting antivirals (DAA) is associated with improvements 
in hemoglobin A1c (HbA1c) and if type 2 diabetes mel-
litus (T2DM) or metabolic syndrome affects sustained 
virologic response (SVR).
METHODS
We performed a retrospective analysis of all hepatitis 
C virus (HCV) patients at the VA Greater Los Angeles 
Healthcare System treated with varying DAA therapy 
between 2014-2016. Separate multivariable logistic 
regression was performed to determine predictors of 
HbA1c decrease ≥ 0.5 after DAA treatment and pre-
dictors of SVR 12-wk post treatment (SVR12).
RESULTS
A total of 1068 patients were treated with DAA therapy 
between 2014-2016. The presence of T2DM or meta-
bolic syndrome did not adversely affect SVR12. 106 
patients had both HCV and T2DM. Within that cohort, 
patients who achieved SVR12 had lower mean HbA1c 
pre treatment (7.35 vs  8.60, P  = 0.02), and lower mean 
HbA1c post-treatment compared to non-responders 
(6.55 vs  8.61, P  = 0.01). The mean reduction in HbA1c 
after treatment was greater for those who achieved 
SVR12 than for non-responders (0.79 vs  0.01, P  = 0.03). 
In adjusted models, patients that achieved SVR12 were 
more likely to have a HbA1c decrease of ≥ 0.5 than 
those that did not achieve SVR12 (adjusted OR = 7.24, 
95%CI: 1.22-42.94). 
CONCLUSION
In HCV patients with T2DM, successful treatment with 
DAA was associated with a significant reduction in HbA1c 
suggesting that DAA may have a role in improving insulin 
sensitivity. Furthermore, the presence of T2DM or meta-
bolic syndrome does not adversely affect SVR12 rates in 
patients treated with DAA.
Key words:  Hepatitis C virus; Hemoglobin A1c; Diabetes 
mellitus; Direct-acting antivirals; Metabolic syndrome
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The relationship of chronic hepatitis C virus 
(HCV) and type 2 diabetes mellitus is complex and lesser 
is known about its relationship to metabolic syndrome. 
While metabolic syndrome and type 2 diabetes may have 
had negative outcomes during the era of pegylated-
interferon, research is being actively pursued to under-
stand how direct acting antivirals (DAA) may affect these 
comorbidities. In this study, we show that unlike with 
pegylated-interferon, direct active antiviral success rates 
are not affected by the presence of metabolic syndrome. 
We further show that successful treatment of HCV with 
DAAs actually leads to better glycemic control 1-year 
post-treatment.
Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May 
FP, Pisegna JR. Metabolic syndrome does not affect sustained 
virologic response of direct­acting antivirals while hepatitis C 
clearance improves hemoglobin A1c. World J Hepatol 2018; 
10(9): 612­621  Available from: URL: http://www.wjgnet.
com/1948­5182/full/v10/i9/612.htm  DOI: http://dx.doi.
org/10.4254/wjh.v10.i9.612
INTRODUCTION
Hepatitis C virus (HCV) infection is a major worldwide 
health problem. It is one of the most common blood-
borne infections in the United States with an estimated 
2.7 million people chronically infected in the United 
States[1]. HCV is also one of the leading causes of cirrh-
osis and liver transplantation[1,2]. There are increasing 
reports indicating an association between HCV and 
type 2 diabetes mellitus (T2DM). Individuals with HCV 
are more likely to have risk factors to develop T2DM 
and patients with T2DM have at least a 2-fold greater 
risk of developing HCV infection than the general po-
pulation[3,4]. 
Prior studies have shown that chronic HCV infection 
is associated with a greater risk for the development 
of insulin resistance[5]. In a retrospective analysis of cir-
rhotic patients, those with HCV infection were 10 times 
more likely to have T2DM than those without HCV infe-
ction[5]. There is evidence that patients with chronic 
HCV infection and increased insulin resistance have a 
higher prevalence of hepatic fibrosis, hepatocellular 
carcinoma, and other extrahepatic manifestations[6-9]. 
While there are unclear mechanisms for increased in-
sulin resistance among those with HCV, factors such as 
metabolic syndrome, increased hepatic iron, and serum 
tumor necrosis factor-α have been implicated[10,11]. 
Molecular studies have also shown that the mechanism 
of insulin resistance can differ by HCV genotype. In 
particular, HCV genotype 3 has been shown to be an 
independent risk factor for hepatic steatosis and its viral 
proteins can directly interfere with intracellular insulin 
signaling[12].
Previously standard therapy for HCV required the 
use of pegylated interferon-α (P-IFN) and ribavirin. 
However, these regimens had low sustained virologic 
response (SVR) rates and were poorly tolerated. During 
the era of P-IFN therapy, several studies showed that 
the presence of obesity and/or steatosis led to a redu-
ction of SVR rate in HCV patients[13,14]. In patients with 
diabetes and HCV who were treated with IFN-based th-
erapies, HCV clearance was associated with improved 
insulin resistance and beta cell function[15]. In 2013 and 
2014, approval of newer direct acting antiviral agents 
(DAA) created IFN-free regimens with SVR rates greater 
than 90%, radically changing HCV treatment. Due to 
the novelty of DAA regimen, research is being actively 
pursued in a variety of patient populations. Within the 
Veterans Health Administration (VA), the incidence 
of chronic HCV is 2-3 times higher than the general 
public[16]. Additionally, patients that receive care in the 
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tment with DAA.
Predictor variables
Data extraction included patient demographic, como-
rbidity, laboratory, and medication data from CPRS. 
Demographic data included age, sex, BMI, race, and 
ethnicity. For race and ethnicity, we used one mutually-
exclusive variable that combined concepts of race and 
ethnicity by including Hispanic as a primary race (non-
Hispanic white, non-Hispanic black, Hispanic, Asian, 
other). Comorbidities included the presence of cirrhosis 
by chart review, elevated Fibrosis-4 (Fib-4) score (a 
measure of advanced fibrosis), hyperlipidemia (HLD), 
hypertension (HTN), HIV, and metabolic syndrome as 
identified by ICD9/ICD10 codes or by chart review. A 
cutoff value of 3.25 was used to determine a signifi-
cant Fib-4 score as consistent with prior studies[22]. 
Within the cohort of patients with both HCV and T2DM, 
the presence of cirrhosis, ascites, and hepatic ence-
phalopathy were confirmed by chart review of the 
patient’s hepatology notes. If a patient had cirrhosis, 
clinical laboratory values were used to calculate a 
patient’s Child-Turcotte-Pugh score and Child-Turco-
ttePugh class (CTP). Using a modified World Health 
Organization definition for metabolic syndrome, we de­
fined metabolic syndrome as having at least diabetes 
mellitus and at least two of the following baseline 
characteristics as determined by ICD-9 CM codes, 
ICD-10 CM codes, or by medication review: A BMI ≥ 
30 kg/m2, HTN, and HLD[23]. The presence of HLD was 
used as a surrogate for elevated triglyceride or reduced 
HDL cholesterol as we were unable to accurately obtain 
triglyceride or HDL levels for all patients before statin 
therapy. Furthermore, because many patients did not 
have urine albumin or urine creatine measurements, 
the presence of microalbuminuria was not analyzed. We 
also documented serological virologic clearance at 12-wk 
post treatment (SVR12), HCV genotype, and prior HCV 
treatment for all patients. 
Statistical analysis
We performed proportions to summarize demographic 
and clinical characteristics and used χ2 tests to examine 
differences between patients that did achieve SVR12 
and those that did not. Medians were compared using 
the Wilcoxon rank-sum test, and means were com-
pared using analysis of variance (ANOVA). All means 
are expressed with their respective standard error.
To determine predictors of SVR12, a multivariable 
logistic regression was performed. Due to the rare 
event of DAA failure, to examine the relationship bet-
ween SVR12 and HbA1c, we performed univariable 
and multivariable penalized maximum likelihood logis-
tic regression analyses similar to prior studies[24,25]. 
Predictors included age, sex, race/ethnicity, HCV geno-
type, treatment experienced or naïve, DAA used, and 
comorbid conditions (HTN, DM, HLD, HIV, elevated 
Fib-4, obesity, metabolic syndrome). The reference 
VA also have a higher prevalence of obesity and T2DM 
compared to the general population[17,18]. Thus, the VA 
presents an ideal population to evaluate the relation-
ship between HCV and T2DM. We aim to determine 
if successful treatment with DAA is associated with 
improvements in hemoglobin A1c (HbA1c) and if the 
presence of T2DM or metabolic syndrome affects SVR 
rates.
MATERIALS AND METHODS
Study population and data collection
DAA were introduced to the VA Greater Los Angeles 
Healthcare System (VAGLAHS) at the beginning of 
April 2014. Therefore, we included all patients being 
treated with DAA between April 1st, 2014 and April 
30th, 2016 for this study. We queried the Corporate 
Data Warehouse (CDW), a repository of all clinical data 
within the VA healthcare system, for all patients with an 
International Classification of Disease, Ninth Revision 
and/or Tenth Revision, Clinical Modification (ICD-9 
CM/ICD-10 CM) diagnosis of HCV and T2DM (ICD-9: 
250.00-250.93, ICD-10: E08-E13). Patients with HCV 
were also included if they had diabetic medications on 
their medication list during the study period. Patients 
were excluded from the cohort if they did not have 
SVR12 data or HbA1c one year after completion of DAA 
therapy. In addition to the CDW query, we manually 
extracted patient clinical and demographic data as well 
as confirm the diagnosis of T2DM from the VA electronic 
medical records, the Computerized Patient Record 
System (CPRS), of all patients screened to have both 
HCV and T2DM by ICD-9 CM or ICD-10 CM codes.
Outcome variables
The primary outcome was the change in HbA1c before 
and after DAA treatment. The secondary outcomes of 
interest were change in body mass index (BMI) over the 
same time period and if the presence of T2DM or other 
traits of metabolic syndrome such as hyperlipidemia 
(HDL), hypertension (HTN), or obesity affected SVR12. 
Serial BMI and HbA1c values were obtained from the 
year before and the year after HCV treatment and sum-
marized as one-year pre-treatment and one-year post-
treatment averages, respectively. A significant change 
of HbA1c was defined as a difference of 0.5 or greater, 
consistent with prior similar studies[19,20]. Through chart 
review, we also documented whether a patient had an 
increase or decrease in oral hypoglycemic dose and/or 
injectable insulin dose from one year before to one 
year after treatment with DAA. A change of greater 
than 10% from baseline was considered a significant 
change in medication, similar to prior studies[21]. Daily 
insulin was calculated as a total amount of basal and/or 
meal-time insulin over a 24-h period as documented 
in the patient’s medication list. We also documented if 
there was a change in the overall number of diabetes 
medications from one year before to one year after trea-
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group was female, white, treatment experienced, low 
Fib-4, without HTN/HLD/metabolic syndrome, genotype 
1a, and treated with sofosbuvir/simeprevir. In addition 
to this model, we performed sub-analyses to determine 
associations between SVR12 and change in insulin 
dose required before and after DAA therapy. Statistical 
assistance was provided by the Institute for Digital 
Research and Education at UCLA. This study along with 
a waiver of informed consent was approved by the 
VA Institutional Review Board and the Research and 
Development Committee at VAGLAHS. 
RESULTS
Cohort characteristics
A total of 1068 patients met inclusion criteria. Baseline 
characteristics are summarized in Table 1. In all pati-
ents treated with DAA, SVR12 rates differ by age, Fib-4 
score, HCV genotype, DAA therapy, and DAA planned 
duration of treatment. Patients who achieved SVR12 
were older (62.0 years vs 60.7 years, P = 0.02). Pati-
ents with a Fib-4 score < 3.25 had an SVR12 rate of 
90.9% as compared to 80.2% for patients with a Fib-4 
score ≥ 3.25. SVR12 rates were varied by HCV geno-
type, with genotype 2 and 3 having lower SVR12 rates 
than genotype 1 (P < 0.01). SVR12 rates also were 
varied by treatment and duration of therapy. SVR12 
rates were highest for patients treated with shorter 
duration (8 and 12 wk as compared to 16 and 24 wk) 
and with sofosbuvir/ledipasvir (93.7%) as compared to 
other regimens. 
Of the 1068 patients treated with DAA, 106 pati-
ents concomitantly had T2DM and HCV and at least 
one HbA1c value 1-year post SVR12 (Table 2). The av-
erage age was 63.2 years (0.5). Within the cohort, 
105 (99.1%) were male, 29 (27.4%) were white, 39 
(36.8%) were African-American, and 27 (25.5%) were 
Hispanic. A total of 98 patients (92.5%) achieved SVR12 
and 8 patients (7.5%) did not achieve SVR12. Fifty-
seven patients (53.8%) had cirrhosis with a majority 
(82.5%) being compensated (i.e., CTP A). Seventy-two 
patients (67.9%) were treatment-naïve while 34 patients 
(32.1%) had been treated with pegylated-interferon 
in the past. The majority of patients had genotype 1a 
(n = 60, 56.6%) or 1b (n = 24, 22.6%) disease. Only 
16 patients (15.1%) had a normal BMI at the time of 
treatment (≥ 18 and < 25) while the rest had a BMI ≥ 
25. Only 3 patients (2.8%) were co-infected with HIV. 
Ninety­five patients (89.6%) had HTN, 79 (74.5%) had 
HLD, and 85 (80.2%) had metabolic syndrome. 
The average age for patients who achieved SVR12 
was higher than those who did not (63.5 years vs 59.6 
years, respectively, P = 0.04). There were no significant 
differences between patients who achieved SVR12 and 
those who did not in regards to sex, race/ethnicity, 
presence of cirrhosis, prior treatment experience, HCV 
genotype, treatment regimen, BMI, HIV status, HTN, 
HLD, or metabolic syndrome (Table 2). 
Changes in HbA1c and BMI
Overall, average HbA1c was significantly lower after 
DAA therapy: 7.44% vs 6.71%, P = 0.01. For the sub-
group of patients that achieved SVR12, the average 
HbA1c before treatment was significantly higher than 
the average after treatment (7.35% vs 6.55%, P 
< 0.01). When SVR12 was not achieved, however, 
HbA1c was not significantly different before and after 
treatment: 8.60% vs 8.61%, P = 0.99 (Table 3). This 
relationship was preserved across all genotypes with 
the greatest difference occurring in genotype 3 (Table 
3). However, there was no difference in the change of 
HbA1c between genotypes or treatment regimens (Table 
4).
Forty-six patients were on insulin before treatment 
and 43 patients were on insulin after treatment. Of 
those patients who were on insulin, the average daily 
insulin requirement before treatment was 55.1 IU 
(5.7) and 49.7 IU (6.2) after treatment (P = 0.50). For 
patients on insulin who achieved SVR12, the average 
daily insulin requirement before treatment was 55.0 
IU (5.85) and the average daily insulin requirement 
after treatment was 48.2 IU (6.30) (P = 0.42). Insulin 
requirement also did not change significantly for pat­
ients who did not achieve SVR12 [55.5 IU (20.4) vs 
58.1 IU (21.8), P = 0.93]. No patients analyzed were 
on any non-insulin injectable diabetes medications. 
There was no difference between the number of dia-
betes medications per patient before or after DAA 
therapy (1.23 vs 1.26, P = 0.43). 
The study included 44 patients (41.5%) defined as 
overweight (BMI ≥ 25), 30 (28.3%) that were defined 
as obese (BMI ≥ 30), and 12 (10.4%) with severe 
obesity (BMI ≥ 40). The average BMI for all patients 
before treatment was 30.1 kg/m2 (0.53), and the 
average BMI for all patients after treatment was 30.2 
kg/m2 (0.54) (P = 0.92). For patients who achieved 
SVR12, the average BMI before and after treatment 
were not statistically different: 30.3 kg/m2 (0.56) vs 
30.3 kg/m2 (0.57), P = 0.96. Similarly, the average BMI 
was not different before and after treatment for the 
patients that did not achieve SVR12: 28.8 kg/m2 (1.4) 
vs 29.2 kg/m2 (1.5), P = 0.92. 
SVR12 is not affected by the components of metabolic 
syndrome
After adjusting for age, sex, race/ethnicity, cirrhosis, 
treatment experience, HCV genotype, treatment 
regimen, HIV status, and treatment duration, the 
individual components of metabolic syndrome (obesity, 
HTN, HLD, and T2DM) and the presence of metabolic 
syndrome itself did not predict SVR12 (Table 5). For 
the full logistic regression for SVR12, please see sup-
plemental Table 1. 
SVR12 as a predictor of improved insulin resistance
When adjusting for age, sex, race/ethnicity, cirrhosis, 
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treatment experience, HCV genotype, treatment re-
gimen, obesity, HIV status, HTN, HLD, and metabolic 
syndrome, SVR12 significantly predicted a 0.5-unit 
improvement in HbA1c with treatment in patients 
with both T2DM and HCV: Adjusted OR (aOR) = 7.24 
(95%CI: 1.22-42.94) (Table 6). Patients who achieved 
SVR12 were also significantly less likely to require 
an increase in insulin after HCV therapy than those 
who did not achieve SVR12: aOR = 0.166 (95%CI: 
0.03-0.74). A decrease of HbA1c was not associated 
with an increase in oral hypoglycemic dose (aOR = 1.07, 
95%CI: 0.48-1.35) or injectable insulin dose (aOR = 
0.6, 95%CI: 0.57-1.87) after DAA therapy.
DISCUSSION
This study demonstrates that HCV clearance with DAAs 
is associated with a clinically significant decrease in 
HbA1c independent of other demographic and clinical 
factors such as metabolic syndrome and BMI. This 
data corroborates recent studies that showed similar 
outcomes with DAA therapy[26]. While Hum et al[26] att-
empted to control for DM medication use by looking at 
the percent of patients taking any DM medication or 
by the number of DM medication class, being unable 
to look at dosage change or changes in medication for 
an individual patient was a limitation of their study. 
Table 1  Baseline characteristics of all patients treated with direct-acting antivirals n  (%)
All patients (n  = 1068) SVR12 not achieved (n  = 138) SVR12 achieved (n  = 930) P -value
Age (mean ± SE, yr) 61.8 ± 0.2 60.7 ± 0.5 62.0 ± 0.2 0.02
Sex 
   Male                     97.5 (1041) 12.8 (133)  87.2 (908) 0.78
   Female                           2.5 (27) 18.500 (5)  81.50 (22)
Race/ethnicity
   White 37.5 (400) 11.00 (44) 89.0 (356) 0.14
   African American 37.5 (401) 14.70 (59) 85.3 (342)
   Hispanic 15.1 (161) 16.80 (27) 83.2 (134)
   Asian                           0.70 (7)   14.30 (1) 85.700 (6)
   Other     9.3 (99)     7.10 (7) 92.90 (92)
   Fib4 < 3.25 64.6 (690)     9.1 (63) 90.9 (627)        < 0.01
   Fib4 ≥ 3.25 35.4 (378) 19.80 (75) 80.2 (303)
   Treatment naïve 79.5 (849) 16.4 (102) 83.6 (747) 0.09
   Treatment experienced 20.5 (219) 16.40 (36) 83.6 (183)
HCV genotype 
   HCV genotype 1a 58.0 (619) 12.10 (75) 87.9 (544)        < 0.01
   HCV genotype 1b 25.9 (277) 10.10 (28) 89.9 (249)
   HCV genotype 2     7.9 (84) 21.40 (18) 78.60 (66)
   HCV genotype 3     6.9 (74) 23.00 (17) 77.00 (57)
   HCV genotype 4     1.2 (13)     0.00 (0) 100.0 (13)
   HCV genotype 6                           0.10 (1)     0.00 (0)   100.0 (1)
Treatment 
   PrOD     4.5 (48)     8.30 (4) 91.70 (44) 0.01
   PrOD/RBV 17.6 (188) 14.40 (27) 85.6 (161)
   Sofosbuvir/Ledipasvir 34.4 (367)     6.3 (23) 93.7 (344)
   Sofosbuvir/Ledipasvir/RBV 13.4 (143) 13.30 (19) 86.7 (124)
   Sofosbuvir/RBV    9.8 (105) 23.80 (25) 76.20 (80)
   Sofosbuvir/Simeprevir 17.5 (187) 19.80 (37) 80.2 (150)
   Other regimens     2.9 (30)     10.0 (3) 90.00 (27)
   No HIV   96.7 (1033) 13.1 (135) 86.9 (898) 0.44
   HIV     3.3 (35)     8.60 (3) 91.40 (32)
Duration of treatment
   8 wk 19.9 (213)     6.6 (14) 93.4 (199)        < 0.01
   12 wk 73.1 (781) 13.4 (105) 86.6 (676)
   16 wk     2.8 (30) 40.00 (12) 60.00 (18)
   24 wk     4.1 (44)   15.90 (7) 84.10 (37)
   BMI < 30 66.5 (710) 12.50 (89) 87.5 (621) 0.60
   BMI > 30 33.5 (358) 13.70 (49) 86.3 (309)
   No HTN 43.7 (467) 13.30 (62) 86.7 (405) 0.76
   HTN 56.3 (601) 12.60 (76) 87.5 (525)
   No T2DM 85.6 (914) 12.4 (113) 87.6 (801) 0.15
   T2DM 14.4 (154) 16.20 (25) 83.8 (129)
   No HLD 58.1 (620) 14.50 (90) 85.5 (530) 0.70
   HLD 41.9 (448) 10.70 (48) 89.3 (400)
   No metabolic syndrome 87.1 (930) 13.0 (121) 87.0 (809) 0.84
   Metabolic syndrome 12.9 (138) 12.30 (17) 87.7 (121)
PrODL: Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir; Fib4: Fibrosis 4 score; RBV: Ribavirin; BMI: Body mass index; HTN: Hypertension; T2DM: Type 2 
diabetes mellitus; HLD: Hyperlipidemia; SVR: Sustained virologic response; HCV: Hepatitis C virus.
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By analyzing each individual patient and examining 
both changes in the number of DM medication and 
the dosage, we find that the change of HbA1c was 
not due to an increase in oral hypoglycemic or insulin 
treatment. The findings imply that the change in 
HbA1c was most likely due to a change in host insulin 
resistance due to HCV clearance. This is in line with 
a recent study showing that HCV clearance with DAA 
reverses insulin resistance[27]. Our finding, however, 
is contrary to what Chaudhury et al[28] described in 
their recent paper published in December of 2017. 
While their study showed no change in HbA1c with 
DAA therapy, only 17% of patients had diabetes and 
their average baseline HbA1c was 5.75%. A reduction 
in HbA1c in a non-diabetic patient is hard to achieve. 
Therefore, it is reasonable to suggest that if they only 
examined patients with T2DM with a baseline HbA1c 
≥ 6.5% they would have found similar conclusions. 
Our data is further corroborated by data showing that 
successful treatment with DAA is also associated with 
a decreased likelihood of requiring higher insulin doses 
for DM management. This is contrary to a paper by 
Stine et al[29] showing that a third of patients required 
an increase in their DM medication after DAA therapy. 
However, they only examined patients up to the time 
of SVR12. It is possible that if they examined data one 
year after SVR12 they would have had similar results. 
Our study also shows that changes in HbA1c did not 
vary between HCV genotype and DAA treatment re-
gimen, implying that HCV clearance itself plays an 
important role in insulin resistance. Even though the 
baseline HbA1c was different in those who did achieve 
SVR12 compared to those that did not, our study shows 
that metabolic syndrome or its individual components 
Table 2  Baseline characteristics of patients with hepatitis C virus and type 2 diabetes mellitus
All patients (n  = 106) SVR12 not achieved (n  = 8) SVR12 achieved (n  = 98) P -value
Age (mean ± SD, yr) 63.2 ± 0.5 59.6 ± 1.4 63.5 ± 0.5 0.04
Sex
   Male 99.1 (105) 7.60 (8) 92.40 (97) 0.74
   Female     0.90 (1) 0.00 (0)   100.0 (1)
Race/ethnicity
   White 27.40 (29) 6.90 (2) 93.20 (27) 0.15
   African American 36.80 (39) 5.10 (2) 94.90 (37)
   Hispanic 25.50 (27) 11.1 (3) 88.90 (24)
   Asian     1.90 (2) 50.0 (1)   50.00 (1)
   Other     8.50 (9) 0.00 (0)   100.0 (9)
Cirrhosis 
   Yes 53.80 (57) 8.80 (5) 91.20 (52) 0.61
   No 46.20 (49) 6.10 (3) 93.90 (46)
CTP class 
   CTP A 82.50 (47) 6.40 (3) 93.60 (44) 0.21
   CTP B   14.00 (8) 25.0 (2)     75.0 (6)
   CTP C     3.50 (2) 0.00 (0)   100.0 (2)
Treatment status
   Naive 67.90 (72) 5.60 (4) 94.40 (68) 0.26
   Experienced 32.10 (34) 11.8 (4) 88.20 (30)
HCV genotype
   Genotype 1a 56.60 (60) 10.0 (6) 90.00 (54) 0.67
   Genotype 1b 22.60 (24) 4.20 (1) 95.80 (23)
   Genotype 2 12.30 (13) 0.00 (0) 100.0 (13)
   Genotype 3     7.60 (8) 12.5 (1)   87.50 (7)
   Genotype 4     0.90 (1) 0.00 (0)   100.0 (1)
Treatment regimen 
   Sofosbuvir/Simeprevir 39.60 (42) 7.10 (3) 92.90 (39) 0.96
   Sofosbuvir/Ribavirin 17.00 (18) 5.60 (1) 94.40 (17)
PrOD 18.90 (20) 10.0 (2) 90.00 (18)
   Sofosbuvir/Ledipasvir 24.50 (26) 7.70 (2) 92.30 (24)
Body mass index 
   Normal 15.10 (16) 6.20 (1) 93.80 (15) 0.78
   Overweight 41.50 (44) 9.10 (4) 90.90 (40)
   Obese 28.30 (30) 6.70 (2) 93.30 (28)
   Severely obese 10.40 (12) 8.30 (1) 91.70 (11)
   Very severely obese     4.70 (4) 0.00 (0)   100.0 (4)
Co-HIV infection     2.80 (3)                       100.0 (3)       0.0 (0) 0.62
HTN 89.60 (95) 8.40 (8) 91.60 (87) 0.32
HLD 74.50 (79) 6.30 (5) 93.70 (74) 0.42
Metabolic syndrome 80.20 (85) 7.10 (6) 92.90 (79) 0.71
HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; HTN: Hypertension; HLD: Hyperlipidemia; PrOD: Ombitasvir/Paritaprevir/Ritonavir/ 
Dasabuvir; SVR: Sustained virologic response; CTP: Child-Turcotte-Pugh.
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(HTN, T2DM, Obesity, HLD) does not negatively affect 
SVR12 rates. 
Prior studies have demonstrated an association 
between HCV infection and host metabolism. It has 
been shown that the hepatitis C virus depends on host 
lipids for entry and replication in hepatocytes[30-32]. 
HCV infection, in return, leads to a disruption of host 
metabolism, which can result in insulin resistance, lipid 
dysregulation, and hepatic steatosis[33]. 
The data represented here are consistent with data 
during the pegylated-interferon era where SVR clea-
rance was associated with decreased insulin resistance 
and improved beta-cell function[10,15,34,35]. Kawaguchi et 
al[15], for example, demonstrated a three-fold increase 
in insulin receptor substrate 1 and 2 expressed in he-
patocytes in 29 biopsy-proven HCV infection who 
maintained SVR after pegylated-interferon therapy. 
They also demonstrated a correlation between serum 
ferritin and homeostatic model assessment (HOMA) 
of β-cell function. Their data supports prior data that 
shows hepatic iron-induced oxidative stress may 
be related to insulin resistance[36]. Knobler et al[11] 
proposed an alternative mechanism in which HCV 
infection may mediate diabetes. In a comparison of 
23 patients with DM and HCV to 28 patients with HCV 
alone, they showed that serum TNF-α levels were 
more prominent in those with concurrent DM. This is 
similar to prior data that shows that TNF-α signaling 
may be related to obesity and insulin resistance, 
thus suggesting a role of inflammation in creating a 
“diabetogenic” state[37]. 
During the era of pegylated-interferon, Bressler 
et al[14] showed that obesity was an independent 
risk factor for reduced SVR12. Because pegylated-
interferon is primarily taken up in the lymphatic sys-
tem and because obese patients have poor lymphatic 
circulation, they proposed that the difference they 
described was due to dissimilar pharmacokinetic pro-
perties of obese and non-obese patients. While that 
may have been true for pegylated-interferon, our 
study shows that obesity, HTN, T2DM, or HLD does 
not significantly affect SVR12 rates of patients on DAA 
therapy. Unsurprisingly, SVR12 rates were reduced in 
patients with an elevated Fib-4 score, in patients with 
genotype 3, and in patients treated with suboptimal 
regimens such as sofosbuvir/ribavirin or sofosbuvir/
simeprevir. This is similar to prior studies showing 
reduced SVR12 in similar treated groups[38-40]. We 
further hypothesized that patients who were more ill 
were more likely to be treated for a longer duration 
thus explaining the discrepancy between SVR rates 
and treatment duration. 
While this study demonstrates the interplay bet-
ween host metabolisms with HCV infection, there 
are certain limitations. The study implies that HCV 
clearance is associated with a reduction in insulin re-
sistance, however, we were unable to measure insulin 
resistance directly before and after treatment. With 
primary care providers preferentially using HbA1c over 
fasting blood glucose, we were unable to use HOMA-
IR (insulin resistance), HOMA-β (β-cell function), or 
other indices of insulin resistance. Nonetheless, HbA1c 
is a well-accepted and commonly utilized method to 
evaluate for insulin sensitivity, and we feel that using 
HbA1c as an outcome is consistent with clinical dia-
gnosis, management, and prior studies[18,20]. Second, 
Table 3  Mean hemoglobin A1c before and after hepatitis C 
virus treatment by hepatitis C virus genotype and sustained 
virologic response 12-wk status
Genotype Before DAA SE After DAA SE P -value
Mean HbA1c of patients who did achieve SVR12
1a 7.5 0.19 6.68 0.14   0.001
1b 7.3 0.22 6.59 0.21 0.03
2   7.09 0.35 6.29 0.21 0.06
3   7.12 0.37 6.10 0.39 0.08
4 5.5 NA 5.30 NA NA
Overall   7.35 0.13 6.55 0.11 < 0.01
Mean HbA1c of patients who did not achieve SVR12
1a   8.98 1.14 8.95 1.41 0.98
1b 6.4 NA 6.50 NA NA
2 No observations
3 8.5 NA 8.70 NA NA
4 No observations
Overall 8.6 0.89 8.61 1.08 0.99
HbA1c: Hemoglobin A1c; SVR12: Sustained virologic response 12 wk after 
treatment; DAA: Direct acting antiviral; SE: Standard error.
Table 4  Mean difference in hemoglobin A1c by hepatitis C 
virus genotype and direct acting antiviral treatment
Average change HbA1c (SE) P -value
HCV genotype
1a -0.73 (0.13) 0.97
1b -0.69 (0.20)
2 -0.79 (0.27)
3 -0.88 (0.51)
4 -0.20 (NA)
Treatment
Sofosbuvir/Simeprevir -0.71 (0.16) 0.97
Sofosbuvir/Ribavirin -0.77 (0.27)
PrOD -0.66 (0.15)
Ledipasvir/Sofosbuvir -0.80 (0.24)
HbA1c: Hemoglobin A1c; HCV: Hepatitis C virus; PrOD: Ombitasvir/
Paritaprevir/Ritonavir/ Dasabuvir
Unadjusted OR (95%CI) Adjusted OR (95%CI)
Obese 0.90 (0.62-1.31) 1.25 (0.82-1.90)
HTN 1.06 (0.74-1.52) 0.81 (0.51-1.28)
HLD 1.42 (0.97-2.10) 1.31 (0.87-1.97)
T2DM 0.72 (0.48-1.10) 0.82 (0.55-1.09)
Metabolic syndrome 1.04 (0.68-1.60) 1.81 (0.75-4.37)
HTN: Hypertension; HLD: Hyperlipidemia; T2DM: Type 2 diabetes 
mellitus.
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our study was a single center study conducted in the 
VA. VA patients are predominantly male and have dif-
ferent socioeconomic factors that may affect health 
as compared to the general population. Nonetheless, 
GLAVA is one of the largest VA medical center that 
includes an integrated network of 12 sites serving a 
racially and ethnically diverse population in Southern 
California. 
In conclusion, this study of a diverse VA patient 
population demonstrates that HCV clearance with DAAs 
is associated with a clinically significant decrease in 
HbA1c. This change was consistent across all genotypes 
and treatment regimens. The change in HbA1c was 
independent of changes in BMI and DM medication 
requirements and so may represent a decrease in 
host insulin resistance or increased insulin sensitivity. 
This study substantiates similar studies during the 
pegylated-interferon era by showing that HCV clearance 
irrespective of treatment regimen and genotype leads 
to improved DM outcomes. However, unlike prior stu-
dies during the period of pegylated-interferon, we 
show that HTN, HLD, T2DM, obesity, and metabolic 
syndrome do not negatively affect SVR12 rates for DAA. 
Future prospective studies analyzing patient fasting 
blood glucose and serum insulin should be performed 
to validate these findings and to help elucidate the 
relationship between HCV, insulin sensitivity, and longer-
term DM outcomes such as cardiovascular events. 
ARTICLE HIGHLIGHTS
Research background
Hepatitis C virus (HCV) infection is a major worldwide health problem. There 
are increasing reports indicating an association between HCV and type 2 
diabetes mellitus (T2DM). Individuals with HCV are more likely to have risk 
factors to develop T2DM and patients with T2DM have at least a 2-fold greater 
risk of developing HCV infection than the general population. Previously st-
andard therapy for HCV required the use of pegylated interferon-α (P-IFN) 
and ribavirin. However, these regimens had low sustained virologic response 
(SVR) rates and were poorly tolerated. During the era of P-IFN therapy, several 
studies showed that the presence of obesity and/or steatosis led to a reduction 
of SVR rate in HCV patients. In patients with diabetes and HCV who were tre-
ated with IFN-based therapies, HCV clearance was associated with improved 
insulin resistance and beta cell function.
Research motivation
In 2013 and 2014, approval of newer direct acting antiviral agents (DAA) 
created IFN-free regimens with SVR rates greater than 90%, radically changing 
HCV treatment. Due to the novelty of DAA regimen, research is being actively 
pursued in a variety of patient populations.
Research ojectives
We aim to determine if successful treatment with DAA is associated with 
improvements in hemoglobin A1c (HbA1c) and if the presence of T2DM or 
metabolic syndrome affects SVR rates.
Research methods
DAA were introduced to the VA Greater Los Angeles Healthcare System 
(VAGLAHS) at the beginning of April 2014. Therefore, we included all patients 
being treated with DAA between April 1st, 2014 and April 30th, 2016 for this study. 
 
Table 6  Odds ratio for a decrease of hemoglobin A1c > 0.5 among type 2 diabetes mellitus patients treated with direct acting 
antiviral
Predictor Unadjusted OR (95%CI) Adjusted OR (95%CI)
Age 1.03 (0.95-1.11) 1.07 (0.96-1.20)
Race/ethnicity
   White1 1.58 (0.64-3.91)
   African American 0.89 (0.32-2.43) 0.52 (0.13-2.06)
   Hispanic 0.53 (0.18-1.57) 0.65 (0.16-2.66)
   Asian 0.50 (0.02-8.85) 0.8 (0.04-10.01)
   Other 0.83 (0.16-4.21) 0.98 (0.12-7.90)
   Cirrhosis (by chart review) 0.62 (0.28-1.37) 0.59 (0.20-1.69)
   Treatment naïve 0.84 (0.87-4.59) 2.61 (0.92-7.29)
HCV genotype
   1a1 0.77 (0.35-1.71)
   1b 1.33 (0.49-3.60) 0.79 (0.22-2.86)
   2 1.50 (0.41-5.42)     6.75 (0.26-176.51)
   3 0.66 (0.15-2.92)    3.81 (0.29-50.00)
Treatment regimen
   Sofosbuvir/Simeprevir1 1.23 (0.55-2.75)
   Sofosbuvir/Ribavirin 0.75 (0.27-2.09)   0.07 (0.003-1.50)
   PrOD 1.60 (0.56-4.56) 0.71 (0.17-2.86)
   Ledipasvir/Sofosbuvir 0.66 (0.27-1.62) 0.35 (0.09-1.36)
Overweight 1.36 (0.42-4.35) 0.89 (0.20-1.69)
Obese 1.55 (0.44-5.40) 1.10 (0.20-5.93)
Severely obese 1.08 (0.24-4.94) 0.41 (0.05-3.07)
Very severely obese 0.26 (0.21-3.06)   0.08 (0.003-2.07)
HTN 1.36 (0.38-4.80) 1.15 (0.15-8.86)
HLD 1.69 (0.69-4.09) 1.45 (0.29-7.26)
Metabolic syndrome 1.58 (0.60-4.15) 0.96 (0.10-9.19)
SVR12a                                    10.67 (1.76-64.7)   7.24 (1.22-42.94)
1Reference group; aP < 0.05. HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; HTN: Hypertension; HLD: Hyperlipidemia; SVR12: Sustained 
virologic response 12 wk post-treatment; PrOD: Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir.
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We performed a retrospective analysis of all HCV patients at the VA Greater 
Los Angeles Healthcare System treated with DAA therapy between 2014-2016. 
Separate multivariable logistic regression was performed to determine 
predictors of HbA1c decrease ≥ 0.5 after DAA treatment and predictors of 
SVR 12-wk post treatment (SVR12). Patients with HCV were also included if 
they had diabetic medications on their medication list during the study period. 
Patients were excluded from the cohort if they did not have SVR12 data or a 
HbA1c one year after completion of DAA therapy.
Research results 
A total of 1068 patients were treated with DAA therapy between 2014-2016. 
The presence of T2DM or metabolic syndrome did not adversely affect SVR12. 
106 patients had both HCV and T2DM. Within that cohort, patients who ac-
hieved SVR12 had lower mean HbA1c pre-treatment (7.35 vs 8.60, P = 0.02), 
and lower mean HbA1c post-treatment compared to non-responders (6.55 vs 
8.61, P = 0.01). The mean reduction in HbA1c after treatment was greater for 
those who achieved SVR12 than for non-responders (0.79 vs 0.01, P = 0.03). 
In adjusted models, patients that achieved SVR12 were more likely to have a 
HbA1c decrease of > 0.5 than those that did not achieve SVR12 (adjusted OR 
= 7.24, 95%CI: 1.22-42.94). 
Research conclusions
In conclusion, this study of a diverse VA patient population demonstrates that 
HCV clearance with DAAs is associated with a clinically significant decrease 
in HbA1c. This change was consistent across all genotypes and treatment 
regimens. The change in HbA1c was independent of changes in BMI and 
DM medication requirements and so may represent a decrease in host in-
sulin resistance or increased insulin sensitivity. This study substantiates 
similar studies during the pegylated-interferon era by showing that HCV cl-
earance irrespective of treatment regimen and genotype leads to improved 
DM outcomes. However, unlike prior studies during the period of pegylated-
interferon, we show that hypertension, hyperlipidemia, T2DM, obesity, and 
metabolic syndrome do not negatively affect SVR12 rates for DAA.
Research perspectives
Future prospective studies analyzing patient fasting blood glucose and serum 
insulin should be performed to validate these findings and to help elucidate the 
relationship between HCV, insulin sensitivity, and longer-term DM outcomes 
such as cardiovascular events.
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